THE GENERAL HOSPITAL CORPORATION

• PRESIDENT AND FELLOWS OF HARVARD COLLEGE

  UEI UNVDZNFA8R29

  $2.1M

  Subcontractor to this prime · 2 sub-awards · latest Mar 5, 2024

  • National Institutes of Health
  • “TITLE: IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM TUBERCULOSIS CENTER (IMPAC-TB) DESCRIPTION: AS PART OF THE HARVARD IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM TUBERCULOSIS (IMPACTB) CENTER, THE LABORATORY OF GALIT ALTER WILL LEAD AND PERFORM WORK UNDER THE PROGRAM'S CROSS-CUTTING PROFILING TECHNOLOGY: SYSTEMS SEROLOGY. SPECIFICALLY, SUBRECIPIENT WILL: €¢ PERFORM SYSTEMS SEROLOGY PROFILING ON CLINICAL COHORTS AND ANIMAL STUDIES FROM THE IMPACTB PROGRAM, TO PROBE THE POTENTIAL BIOLOGICAL ROLE OF ANTIBODIES IN DRIVING ANTI-MICROBIAL CONTROL, AS WELL AS GENERATE AND ENGINEER NOVEL MONOCLONAL ANTIBODIES TO FURTHER DISSECT THE MECHANISTIC ROLE OF ANTIBODIES IN BACTERICIDAL ACTIVITY. AS PART OF THE HARVARD IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM TUBERCULOSIS (IMPACTB) CENTER, THE LABORATORY OF GALIT ALTER WILL LEAD AND PERFORM WORK UNDER THE PROGRAM'S CROSS-CUTTING PROFILING TECHNOLOGY: SYSTEMS SEROLOGY.”
  • “RESEARCH - BASE FUNDING AS PART OF THE HARVARD IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM TUBERCULOSIS (IMPACTB) CENTER, THE LABORATORY OF ALEX SHALEK WILL LEAD AND PERFORM WORK UNDER THE PROGRAM€„¢S CROSS-CUTTING PROFILING TECHNOLOGY: SINGLE-CELL RNA SEQUENCING. SPECIFICALLY, SUBRECIPIENT WILL: €¢ FURTHER DEVELOP AND APPLY SEQ-WELL, A PLATFORM HE RECENTLY DEVELOPED FOR MASSIVELY PARALLEL SINGLE-CELL RNA-SEQ ON LOW-INPUT CLINICAL SAMPLES. SEQ-WELL WILL BE PERFORMED ON SAMPLES FROM CLINICAL COHORTS AND ANIMAL STUDIES FROM THE IMPACTB PROGRAM, TO PROBE THE POTENTIAL BIOLOGICAL ROLE OF DIVERSE CELL TYPES IN DRIVING ANTI-MICROBIAL CONTROL. €¢ TRAIN IMPACTB COLLABORATORS IN THE USE OF SEQ-WELL, INCLUDING BOTH VISITING AND HOSTING TRAINEES FROM COLLABORATING LABS. AS PART OF THE HARVARD IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM TUBERCULOSIS (IMPACTB) CENTER, THE LABORATORY OF ALEX SHALEK WILL LEAD AND PERFORM WORK UNDER THE PROGRAM€„¢S CROSS-CUTTING PROFILING TECHNOLOGY: SINGLE-CELL RNA SEQUENCING. SPECIFICALLY, FOR THE €œOPTIONAL STUDIES" PROJECT 1 SIV-BCG IV€Ͽ½ SUBRECIPIENT WILL: €¢ PERFORM SEQ-WELL ON NON-HUMAN PRIMATE SAMPLES FROM PROJECT 1 FROM THE IMPACTB PROGRAM, TO PROBE THE POTENTIAL BIOLOGICAL ROLE OF DIVERSE CELL TYPES IN DRIVING ANTI-MICROBIAL CONTROL.”
• TRIAD NATIONAL SECURITY, LLC

  UEI X7WUS5LRBQU3

  $709.2K

  Subcontractor to this prime · 1 sub-award · latest Aug 15, 2024

  • Department of Energy
  • “MASSACHUSETTS GENERAL HOSPITAL-STANDALONE-ITEM LEVEL-R AND D”
• SEATTLE CHILDREN'S HOSPITAL

  UEI SZ32VTCXM799

  $451.1K

  Subcontractor to this prime · 1 sub-award · latest Jan 31, 2024

  • National Institutes of Health
  • “THROUGH THE EXECUTION OF THIS CONTRACT, WE WILL EXAMINE BASIC INDUCTION OF INNATE AND ADAPTIVE IMMUNITY FROM VACCINATION, INCLUDING STUDIES THAT ADDRESS NTM INTERFERENCE, RNA DELIVERY, PRIME-BOOST REGIMENS (INCLUDING BCG PRE-EXPOSURE), TRANSCRIPTOMIC HOST SIGNATURES, PROTEOMICS, SYSTEMS BIOLOGY AND DURABLE IMMUNE MEMORY FOR THE FURTHER ADVANCEMENT OF THE EFFORT TO DESIGN AND EVALUATE AN EFFICACIOUS VACCINE AGAINST MYCOBACTERIUM TUBERCULOSIS (M.TB). OPTION 3 ACTIVITIES: EVALUATE OPTIMIZED M.TB VACCINE CANDIDATES FOR SAFETY, IMMUNOGENICITY AND EFFICACY IN THE NHP MODEL OF TB SCRI HAS WORKED WITH DR. RYAN MCNAMARA AT THE RAGON INSTITUTE TO DEVELOP A WORKPLAN FOR THE SYSTEM SEROLOGY ENDPOINTS FOR BOTH CLINICAL AND PRECLINICAL EVALUATIONS. WE HAVE CONFIRMED THAT A LIST OF 207 M.TB ANTIGENS THAT WERE RECENTLY PUBLISHED ARE NOT PROPRIETARY TO RAGON AND ARE AN APPROPRIATE SET FOR OUR INVESTIGATIONS. TASK 3.7 COMPARE IMMUNE PROFILES IN NHP, SMALL ANIMAL MODELS AND HUMANS TO IDENTIFY CORRELATES OF PROTECTION. SUBTASK 3.7.1 EVALUATE HUMORAL IMMUNITY AS A VACCINE-INDUCED CORRELATE OF PROTECTION USING SYSTEMS SEROLOGY IN THE NHP MODEL. SEVERAL EFFECTOR FUNCTIONS BASED ON THE FC PORTION OF THE ANTIBODY CAN CONTRIBUTE TO THE CLEARANCE OF ORGANISMS, INCLUDING COMPLEMENT ACTIVITY, ANTIBODY-DEPENDENT CELLULAR PHAGOCYTOSIS (ADCP), ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY (ADCC), ANTIBODY-DEPENDENT CYTOKINE AND CHEMOKINE SECRETION. SYSTEMS SEROLOGY ANALYSIS WILL BE USED TO EVALUATE ANTIBODY EFFECTOR FUNCTIONS INCLUDING NK CELL ACTIVATION, ADCP, AND ADCC. THESE ASSAYS CAPTURE OVER 100 BIOPHYSICAL AND FUNCTIONAL CHARACTERISTICS OF POLYCLONAL ABS, INCLUDING CYTOLYTIC ACTIVITY, PHAGOCYTIC TARGET CLEARANCE, CYTOKINE SECRETION, AND IMMUNOMODULATOR RELEASE. THIS SUITE OF FUNCTIONAL ASSAYS WILL BE UTILIZED TO BROADLY DEFINE THE FC PROFILES OF ID93- AND BCG-SPECIFIC ABS. FOR ALL FUNCTIONAL ASSAYS, THE FUNCTIONAL ACTIVITY OF ABS WILL BE ASSESSED AGAINST ID93, PPD, INFLUENZA HEMAG”

• TRUSTEES OF TUFTS COLLEGE

  UEI C1F5LNUF7W86

  $709.9K

  Subcontracted by this company · 1 sub-award · latest Oct 30, 2024

  • Centers for Disease Control and Prevention
  • “TUFTS UNIVERSITY WILL BE RESPONSIBLE FOR IDENTIFYING PATIENTS WITH LYME DISEASE IN THE TUFTSMEDICINE HOSPITAL AND PRIMARY CARE NETWORK THROUGH REGULARLY SCHEDULED ELECTRONIC HEALTH RECORDS (EHR) SCANS AND EXTRACTING CLINICAL INFORMATION TO PROVIDE DEIDENTIFIED DETAILS OF THE DISEASE TO A COMBINED DATABASE AT MASSACHUSETTS GENERAL HOSPITAL (MGH) FOR SUBSEQUENT TRANSMISSION TO THE CDC. TUFTS UNIVERSITY INVESTIGATORS WILL WORK WITH MGH INVESTIGATORS TO CREATE A UNIFIED AND EFFECTIVE CASE DEFINITION FOR IDENTIFYING PATIENTS WITH LYME DISEASE.TUFTS UNIVERSITY INVESTIGATORS WILL ASSIST IN THE MODEL DEVELOPMENT, VALIDATION, AND DEPLOYMENT PROCESS AS DESCRIBED IN THE FULL PROPOSAL. WE WILL FIRST DEVELOP A BASELINE MODEL OF SUBJECTS PRESENTING TO TUFTSMEDICINE WHO ARE DIAGNOSED AS HAVING LYME DISEASE BY ICD9/10 CODES. WE WILL THEN WORK WITH MASS GENERAL BRIGHAM AND MAINEHEALTH TO DERIVE ONE OR MORE IMPROVED MODELS BY IDENTIFYING INFORMATIVE DIAGNOSTIC CRITERIA FROM CLINICAL, MICROBIOLOGICAL, EPIDEMIOLOGY, AND FREE TEXT DATA IN CASE AND CONTROL VISITS. WE WILL COMPARE THE PERFORMANCE OF ONE OR MORE IMPROVED MODELS AND SELECT THE BEST-PERFORMING ONE. WE WILL IMPLEMENT THE BEST-PERFORMING MODEL FOR RECORDS AT TUFTS UNIVERSITY, SUMMARIZE THE RESULTS, AND AGGREGATE SUMMARY STATISTICS ACROSS SITES.”
• MAINEHEALTH

  UEI MAYKB1LWD5U9

  $672.6K

  Subcontracted by this company · 1 sub-award · latest Oct 30, 2024

  • Centers for Disease Control and Prevention
  • “DR. ROBERT SMITH AND COLLEAGUES AT MAINEHEALTH AND MAINEHEALTH INSTITUTE FOR RESEARCH WILL IDENTIFY PATIENTS WITH LYME DISEASE IN THE MAINEHEALTH SYSTEM THROUGH REGULARLY SCHEDULED ELECTRONIC MEDICAL HEALTH RECORD (EPIC) SCANS AND EXTRACT CLINICAL INFORMATION TO PROVIDE DE€Ͽ½IDENTIFIED DETAILS OF DISEASE TO A COMBINED DATA BASE IN CONCERT WITH A COORDINATED APPROACH AT MASSACHUSETTS GENERAL HOSPITAL (MGH) AND TUFTSMEDICINE. AGGREGATED DATA WILL BE SHARED WITH RESEARCHERS AT THE FEDERAL CENTERS FOR DISEASE CONTROL TO BETTER UNDERSTAND THE HEALTH BURDEN AND OUTCOMES IN OF LYME DISEASE IN OUR HIGHLY ENDEMIC REGION. MAINEHEALTH INSTITUTE FOR RESEARCH INVESTIGATORS UNDER DR. SMITH€„¢S DIRECTION WILL WORK WITH MGH AND TUFTS TEAMS TO CREATE A UNIFIED AND EFFECTIVE CASE DEFINITION FOR IDENTIFYING PATIENTS WITH LYME DISEASE. DR. SMITH, WITH THE ASSISTANCE OF INFECTIOUS DISEASE COLLEAGUE DR. STEPHEN RAWLINGS, WILL ASSIST A TRAINED CLINICAL STUDY COORDINATOR IN CASE IDENTIFICATION AND DATA EXTRACTION. DR. SUSAN ELIAS WILL OVERSEE DATA MANAGEMENT AT THE MHIR SITE AND CO€Ͽ½ORDINATE WITH THE TEAMS AT MGH AND TUFTSMEDICINE TO ASSURE STANDARDIZATION. THE FIRST YEAR OF WORK WILL INVOLVE COORDINATED (MGH, TUFTS, MAINEHEALTH) MODEL DEVELOPMENT, VALIDATION, AND DEPLOYMENT AS DESCRIBED IN THE FULL PROPOSAL. WE WILL FIRST CREATE A BASELINE MODEL OF SUBJECTS WHO ARE DIAGNOSED AS HAVING LYME DISEASE BY ICD9/10 CODES. WE WILL THEN WORK TO DERIVE IMPROVED MODELS BY IDENTIFYING INFORMATIVE DIAGNOSTIC CRITERIA FROM CLINICAL, EPIDEMIOLOGICAL, MICROBIOLOGICAL AND FREE TEXT DATA IN CASE AND CONTROL VISITS. WE WILL COMPARE THE PERFORMANCE OF ONE OR MORE IMPROVED MODELS AND SELECT THE BEST PERFORMING ONE. WE WILL IMPLEMENT THE SELECTED MODEL FOR RECORD REVIEW AT MAINEHEALTH, SUMMARIZE THE RESULTS, AND AGGREGATE SUMMARY STATISTICS ACROSS SITES. BASED UPON A UNIFIED, EFFECTIVE CASE DEFINITION AND A ROBUST MODEL TO IDENTIFY CASES OF LYME DISEASE FROM EPIC DATA, WE WIL”

Agencies generally may not award to excluded parties, and primes may not subcontract with them above the threshold in FAR 52.209-6 (except COTS items) without a compelling reason reported to the contracting officer (FAR 9.405, 9.405-2). Some exclusion types apply only to specific programs: read the record on SAM.gov.

No confirmed match on the Consolidated Screening List (screened Nov 13, 2026).

The list combines Commerce, State and Treasury export-control and sanctions lists. A “no match” result is a name-and-address screen, not an export-compliance determination.